BACKGROUND: Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). METHODS: Subjects with rheumatoid arthritis participating in several different US insurance programs between 1998 and 2007 who received methotrexate were eligible. Those who added a TNF-α blocking agent were compared with subjects who added a nbDMARD in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage. We examined the composite cardiovascular end point of myocardial infarction, stroke, or coronary re-vascularization after 6 months. RESULTS: We compared 8656 new users of a nbDMARD with 11,587 new users of a TNF-α blocking agent with similar baseline covariates. Incidence rates per 100 person-years for the composite cardiovascular end point were 3.05 (95% confidence interval [CI], 2.54-3.65) for nbDMARDs and 2.52 (95% CI, 2.12-2.98) for TNF-α blocking agents. The hazard ratio (HR) for the TNF-α blocking agent compared with nbDMARD carrying the first exposure forward was 0.80 (95%, CI 0.62-1.04), while the HR for the as-treated analysis was 0.71 (95% CI, 0.52-0.97). The potential cardiovascular benefit of TNF-α blocking agents was strongest among individuals ≥65 years of age (HR 0.52; 95% CI, 0.34 -0.77; P for interaction = 0.075). CONCLUSION: Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis.
BACKGROUND: Elevated tumornecrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritispatients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). METHODS: Subjects with rheumatoid arthritis participating in several different US insurance programs between 1998 and 2007 who received methotrexate were eligible. Those who added a TNF-α blocking agent were compared with subjects who added a nbDMARD in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage. We examined the composite cardiovascular end point of myocardial infarction, stroke, or coronary re-vascularization after 6 months. RESULTS: We compared 8656 new users of a nbDMARD with 11,587 new users of a TNF-α blocking agent with similar baseline covariates. Incidence rates per 100 person-years for the composite cardiovascular end point were 3.05 (95% confidence interval [CI], 2.54-3.65) for nbDMARDs and 2.52 (95% CI, 2.12-2.98) for TNF-α blocking agents. The hazard ratio (HR) for the TNF-α blocking agent compared with nbDMARD carrying the first exposure forward was 0.80 (95%, CI 0.62-1.04), while the HR for the as-treated analysis was 0.71 (95% CI, 0.52-0.97). The potential cardiovascular benefit of TNF-α blocking agents was strongest among individuals ≥65 years of age (HR 0.52; 95% CI, 0.34 -0.77; P for interaction = 0.075). CONCLUSION: Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis.
Authors: Daniel H Solomon; Joel Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Soko Setoguchi; Jeffrey D Greenberg Journal: Ann Rheum Dis Date: 2010-05-05 Impact factor: 19.103
Authors: K M Kurrelmeyer; L H Michael; G Baumgarten; G E Taffet; J J Peschon; N Sivasubramanian; M L Entman; D L Mann Journal: Proc Natl Acad Sci U S A Date: 2000-05-09 Impact factor: 11.205
Authors: Cecilia P Chung; Katherine T Murray; C Michael Stein; Kathi Hall; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2010-06 Impact factor: 2.890
Authors: Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: Seo Young Kim; Amber Servi; Jennifer M Polinski; Helen Mogun; Michael E Weinblatt; Jeffrey N Katz; Daniel H Solomon Journal: Arthritis Res Ther Date: 2011-02-23 Impact factor: 5.156
Authors: Frank I Scott; Ronac Mamtani; Colleen M Brensinger; Kevin Haynes; Zelma C Chiesa-Fuxench; Jie Zhang; Lang Chen; Fenglong Xie; Huifeng Yun; Mark T Osterman; Timothy Beukelman; David J Margolis; Jeffrey R Curtis; James D Lewis Journal: JAMA Dermatol Date: 2016-02 Impact factor: 10.282
Authors: Chun Li; X R Wang; H J Ji; X Y Zhang; X F Li; L Z Wang; C H Wang; Y F Wang; Rong Yang; G C Wang; Xin Lu; Ping Zhu; L N Chen; H T Jin; J T Liu; X Y Liu; Lin Sun; H Y Chen; Ping Wei; J X Wang; L F Cui; Rong Shu; B L Liu; Z L Zhang; G T Li; Z B Li; Jing Yang; J F Li; Bin Jia; F X Zhang; J M Tao; S L Han; J Y Lin; M Q Wei; X M Liu; Dan Ke; S X Hu; Cong Ye; X Y Yang; Hao Li; C B Huang; Ming Gao; Bei Lai; X F Li; L J Song; Yi Wang; X Y Wang; Y D Tang; Yin Su; Rong Mu; Z G Li Journal: Clin Rheumatol Date: 2017-03-24 Impact factor: 2.980